Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Large Decline in Short Interest

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) was the recipient of a large drop in short interest in December. As of December 31st, there was short interest totaling 17,840 shares, a drop of 35.0% from the December 15th total of 27,450 shares. Based on an average daily volume of 25,515 shares, the days-to-cover ratio is currently 0.7 days. Currently, 0.0% of the company’s stock are sold short. Currently, 0.0% of the company’s stock are sold short. Based on an average daily volume of 25,515 shares, the days-to-cover ratio is currently 0.7 days.

Pharming Group Stock Performance

PHAR traded up $0.28 during trading hours on Friday, hitting $18.44. 17,891 shares of the stock were exchanged, compared to its average volume of 24,799. The stock has a market cap of $1.26 billion and a price-to-earnings ratio of -1,842.16. The stock has a 50-day simple moving average of $17.18 and a 200-day simple moving average of $14.46. The company has a debt-to-equity ratio of 0.35, a current ratio of 3.16 and a quick ratio of 2.39. Pharming Group has a 12 month low of $7.50 and a 12 month high of $19.05.

Pharming Group (NASDAQ:PHAR) last issued its earnings results on Thursday, November 6th. The company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of $0.05 by $0.05. Pharming Group had a net margin of 0.30% and a return on equity of 0.46%. The company had revenue of $97.30 million for the quarter, compared to analysts’ expectations of $98.22 million. Analysts anticipate that Pharming Group will post -0.2 earnings per share for the current year.

Hedge Funds Weigh In On Pharming Group

An institutional investor recently bought a new position in Pharming Group stock. EverSource Wealth Advisors LLC purchased a new position in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 2,979 shares of the company’s stock, valued at approximately $32,000. 0.03% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pharming Group in a research report on Monday, December 22nd. Wall Street Zen raised shares of Pharming Group to a “strong-buy” rating in a report on Saturday, December 27th. Finally, Zacks Research downgraded shares of Pharming Group from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 1st. Two investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $38.00.

About Pharming Group

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.